EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors

• Váldodahkkit: Haiyan Xu (Dahkki), Guangjian Yang (Dahkki), Runze Liu (Dahkki), Yaning Yang (Dahkki), Weihua Li (Dahkki), Junling Li (Dahkki), Xuezhi Hao (Dahkki), Puyuan Xing (Dahkki), Yan Wang (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background: Approximately 10% of patients with non-small cell lung cancer (NSCLC) harbor uncommon epidermal growth factor receptor (EGFR) alterations. This study aims to investigate the therapeutic responses and predict the binding activity of different tyrosine kinase inhibitors (TKIs) for EGFR unc...